Compare FOXA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXA | BIIB |
|---|---|---|
| Founded | 2018 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | FOXA | BIIB |
|---|---|---|
| Price | $73.91 | $176.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 22 |
| Target Price | $71.15 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 3.6M | 2.4M |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 9.15 | N/A |
| EPS | 4.44 | ★ 10.97 |
| Revenue | ★ $16,474,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $0.74 | $3.58 |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | $16.64 | ★ $16.07 |
| Revenue Growth | ★ 14.90 | 4.77 |
| 52 Week Low | $46.42 | $110.04 |
| 52 Week High | $74.63 | $185.17 |
| Indicator | FOXA | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 77.78 | 57.23 |
| Support Level | $70.09 | $168.56 |
| Resistance Level | $74.63 | $177.29 |
| Average True Range (ATR) | 1.45 | 4.81 |
| MACD | 0.22 | -1.03 |
| Stochastic Oscillator | 89.50 | 53.27 |
Fox operates in two segments: cable networks and television. Cable networks primarily includes Fox News, Fox Business, and several pay TV sports stations. Television primarily includes the Fox broadcast network, 29 owned and operated local television stations, of which 18 are affiliated with the Fox network, and streaming platform Tubi, which is not subscription-based and is completely ad-supported. Fox effectively sold most of its entertainment assets to Disney in 2019, so it no longer creates entertainment content and relies heavily on live news and sports, with nearly all tied to the pay TV bundle. The Murdoch family controls Fox.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).